Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.52 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12431968 | 0.90 | PLA2G2A (0.62) | PLA2G2APLA2G4B | |
| SCHEMBL11435088 | 0.90 | PLA2G2A (0.62) | PLA2G2APLA2G4B | |
| SCHEMBL38650624 | 0.90 | PLA2G2A (0.62) | PLA2G2APLA2G4B | |
| SCHEMBL12431955 | 0.89 | PLA2G2A (0.59) | PLA2G2APLA2G4B | |
| SCHEMBL6557422 | 0.89 | PLA2G2A (0.64) | PLA2G2APLA2G4BS1PR2S1PR1S1PR3 | |
| SCHEMBL12432454 | 0.89 | PLA2G2A (0.64) | PLA2G2APLA2G4BS1PR2S1PR1S1PR3 | |
| SCHEMBL2307486 | 0.85 | PLA2G2A (0.56) | PLA2G2APLA2G4BS1PR2S1PR1S1PR3 | |
| SCHEMBL1457711 | 0.84 | HTT (0.66) | POLBALOX15HTTPLAU | |
| SCHEMBL5026091 | 0.84 | SLC6A5 (0.56) | PLA2G2APLA2G4B | |
| Hydrochloric Acid SCHEMBL16143391 | 0.83 | SLC6A5 (0.55) | PLA2G2APLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846366-B1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | SLC38A7, SLC7A1, SLC6A7 | PLA2G2A 3858/4885POLB 3886/4885ALOX15 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.